+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Pharmacovigilance & Drug Safety Software Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 196 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968703
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Pharmacovigilance and drug safety software is vital for senior leaders aiming to strengthen regulatory compliance, unify best practices, and promote operational transparency across global life sciences operations. Purpose-built solutions transform how teams manage risk, collaborate, and meet evolving industry obligations.

Market Snapshot: Pharmacovigilance and Drug Safety Software

The global pharmacovigilance and drug safety software market continues to expand as pharmaceutical manufacturers, biotechnology companies, and contract research organizations invest in technology to modernize compliance infrastructures and manage complex workflows. With a total valuation of USD 629.31 million, recent projections show growth to USD 723.35 million in the next year, and nearly USD 1.93 billion by 2032, reflecting a 15.05% compound annual growth rate. Vendors are focusing on modernization and digital transformation by delivering software platforms that streamline adverse event reporting and regulatory submissions, enabling more efficient collaboration and building trust throughout the broader healthcare ecosystem.

Scope & Segmentation: Pharmacovigilance Software Market

Thorough awareness of core market segments supports leaders looking to match technology investments with strategic goals and compliance demands. The market is defined by several critical aspects:

  • Component: Includes advanced analytics, regulatory reporting tools, event detection algorithms, integrated safety databases, and risk assessment features, all essential for secure management of sensitive data and prompt identification of adverse events.
  • Organization Size: Spans from modular platforms for mid-sized teams to full-scale deployments supporting multi-site or complex compliance requirements, allowing scalability as organizational needs evolve.
  • End User: Prioritizes needs of pharmaceutical manufacturers, biotechnology firms, and contract research organizations, each requiring tailored data management and workflow integration.
  • Deployment Mode: Offers flexible options including cloud-based (public or private) and on-premises solutions, aligning system architecture with in-house infrastructure preferences and local regulatory guidelines.
  • Application: Covers adverse event management, comprehensive documentation, ongoing regulatory monitoring, and risk communication for maintaining robust compliance in fast-changing settings.
  • Region: Adoption and deployment strategies differ across the Americas, Europe, Middle East & Africa, and Asia-Pacific, influenced by regulatory frameworks, language, and IT maturity, which shapes compliance priorities and technology selection.
  • Leading Vendors: Oracle Corporation, ArisGlobal LLC, Veeva Systems Inc., EXTEDO GmbH, Ennov Solutions SA, Dassault Systèmes SE, Clarivate Plc, RELX PLC, Lorenz Life Sciences Group GmbH, and Genpact Ltd., each deliver specialized platforms tailored to sector demands.

Understanding these segments enables leaders to select software that enhances data visibility, supports secure collaboration across functions, and adapts to shifting business or regulatory strategies.

Key Takeaways for Senior Decision-Makers

  • Integration of artificial intelligence and machine learning in pharmacovigilance software accelerates detection of risks, enabling decision-makers to anticipate regulatory concerns and take timely, informed action.
  • Cloud-native and modular solutions allow distributed teams to align operations, supporting unified data oversight and fostering effective cross-border collaboration regardless of organizational complexity.
  • Automated system functionality reduces operational impact from software upgrades or migrations, preserving ongoing compliance and supporting future business growth or procedural shifts.
  • Configurable architectures support both enterprise-wide and departmental implementations, ensuring the flexibility needed to accommodate fluctuations in regulatory or operational requirements.
  • Localization for language and regional compliance is increasingly prioritized, with adaptive platforms seeing strong uptake in regions like EMEA and Asia-Pacific to meet local standards and connectivity needs.
  • Lifecycle management features equip organizations to respond quickly to legislative change, maintaining alignment with safety requirements as new regulations emerge.

Tariff Impact: Shaping Software Sourcing and Strategies

Recent U.S. tariff policies have led life sciences organizations to re-evaluate their approach to sourcing and deploying pharmacovigilance and drug safety platforms. Many favor cloud-based solutions due to predictable costs and improved resilience against supply chain uncertainties. Additionally, companies are strengthening domestic IT infrastructure and diversifying vendor relationships to maintain regulatory adherence within a changing policy landscape.

Methodology & Data Sources

This analysis utilizes structured interviews with sector executives and regulatory officials, validated with authoritative industry benchmarks and the latest regulatory documentation. This approach ensures actionable, reliable insights for informed decision-making.

Why This Report Matters

  • Empowers leadership to select technology that supports compliance and helps organizations respond quickly to regulatory demands.
  • Clarifies current technology trends and operational best practices across diverse regions for optimal procurement and risk management strategies.
  • Delivers actionable insights for building resilient and future-proof pharmacovigilance compliance frameworks.

Conclusion

Pharmacovigilance and drug safety software underpin robust and compliant operations. These insights equip senior decision-makers to drive progress in regulatory and operational excellence, supporting sustainable modernization across life sciences organizations.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Integration of artificial intelligence for predictive pharmacovigilance signal detection across global safety databases
5.2. Adoption of real-world evidence analytics to enhance drug safety monitoring and regulatory compliance timelines
5.3. Implementation of cloud-native pharmacovigilance platforms for scalable global case management and collaboration
5.4. Deployment of natural language processing to accelerate extraction of adverse event data from unstructured medical records
5.5. Adoption of robotic process automation to streamline literature screening and expedite safety report generation workflows
5.6. Increasing use of blockchain technology to ensure data integrity and traceability in pharmacovigilance audit trails
5.7. Development of mobile safety reporting applications to empower patients and healthcare professionals for real-time adverse event submission
5.8. Emphasis on global regulatory harmonization initiatives driving standardization of electronic safety data exchange formats
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Pharmacovigilance & Drug Safety Software Market, by Component
8.1. Pharmacovigilance Analytics
8.2. Regulatory Reporting
8.3. Safety Database Management
8.4. Signal Detection And Risk Management
9. Pharmacovigilance & Drug Safety Software Market, by Organization Size
9.1. Large Enterprise
9.2. Small And Medium Enterprise
10. Pharmacovigilance & Drug Safety Software Market, by End User
10.1. Contract Research Organizations
10.2. Pharmaceutical And Biotech Companies
11. Pharmacovigilance & Drug Safety Software Market, by Deployment Mode
11.1. Cloud
11.1.1. Private Cloud
11.1.2. Public Cloud
11.2. On Premise
12. Pharmacovigilance & Drug Safety Software Market, by Application
12.1. Adverse Event Case Management
12.2. Aggregate Reporting
12.3. Risk Communication
12.4. Risk Management
13. Pharmacovigilance & Drug Safety Software Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Pharmacovigilance & Drug Safety Software Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Pharmacovigilance & Drug Safety Software Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Oracle Corporation
16.3.2. ArisGlobal LLC
16.3.3. Veeva Systems Inc.
16.3.4. EXTEDO GmbH
16.3.5. Ennov Solutions SA
16.3.6. Dassault Systèmes SE
16.3.7. Clarivate Plc
16.3.8. RELX PLC
16.3.9. Lorenz Life Sciences Group GmbH
16.3.10. Genpact Ltd.

Companies Mentioned

The companies profiled in this Pharmacovigilance & Drug Safety Software market report include:
  • Oracle Corporation
  • ArisGlobal LLC
  • Veeva Systems Inc.
  • EXTEDO GmbH
  • Ennov Solutions SA
  • Dassault Systèmes SE
  • Clarivate Plc
  • RELX PLC
  • Lorenz Life Sciences Group GmbH
  • Genpact Ltd.

Table Information